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about polio, its consequences and preventionMobile vaccinations teams should be
properly trained to provide better information to the community and role of mass
media should be extended.
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CRITICAL SUCCESS FACTORS FOR THE UPTAKE OF NOVEL VACCINES ONTO
NATIONAL IMMUNUSATION PROGRAMMES
Oshinowo B, Grosvenor A, Ng-Haing J
PriceSpective, London, UK
OBJECTIVES: The HPV (human papillomavirus) vaccine has been one of the most
successful vaccines in the past decade, securing rapid inclusion onto national im-
munization programmes (NIP). By contrast, the HZ (herpes zoster) vaccine, another
recent launch, has failed to gainwidespread coverage. The aimof this research is to
compare these cases based on cost effectiveness in order to understand underlying
criteria for successful vaccine uptake.METHODS:Weconducted a literature review
using databases (Cochrane library, Medline and Google scholar) for the time period
19952010. Key searchwords included HPV, HZ, vaccination, economic evaluation
and cost effectiveness. Extracted studies were selected based on pre-determined
inclusion and exclusion criteria. RESULTS: Despite low incidence rates for cervical
cancer in some countries, the HPV vaccine was considered to be cost effective with
ratios ranging from $14,149 to $29,580/QALY. It provides long term protection in a
young population. Although theHZ vaccine displayed a similar CE range, $16,229 to
$28,325/QALY, this was heavily dependent on age (optimal years being 60-70). Con-
sequently, the HZ vaccine is indicated for the elderly. It is also considered to pro-
vide waning immunity after initial vaccination. From a public health point of view,
the HZ vaccine was not as well received as the HPV vaccine. CONCLUSIONS: In
addition to vaccine efficacy, long term immunity and safety, there are additional
factors which influence vaccine uptake. For example there are substantial public
good aspects of vaccination with long term societal returns reflected in maximal
population coverage. In particular, awareness and support from the medical pro-
fession, particularly general practitioners, also assist in the perception of societal
value that a vaccine can provide. These factors are all very important consider-
ations beyond economic evaluation, and therefore have great influence over inclu-
sion onto NIPs.
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TRENDS IN FUNDING OF SPECIALIST VACCINES
Scott SA, Forster L
Double Helix Consulting, London, UK
OBJECTIVES: This research was conducted to assess how the specialist vaccines
are evaluated and the impact this has had on funding compared tomore traditional
vaccines. METHODS: The study was conducted across the UNITED KINGDOM,
France, Germany, Sweden and Japan. An in-depth piece of secondary research was
undertaken to determine the process of assessing vaccines, focusing on how the
Pricing and market access was achieved by most recent vaccines entering the
market. Short interviews were then conducted with a variety of key vaccine stake-
holders, including payers and key opinion leaders to assess how more specialist
vaccinesmight be reviewedwithin themarket, focusing onwhat product elements
influence use and funding through a national program. RESULTS: The process of
assessing vaccines varies by the market and has seen some changes through po-
litical reforms, although the decision to fund nationally tends to be based on sim-
ilar criteria acrossmarkets. The greatest focus for funding of traditional vaccines is
the patient population and overall benefit, allowing easy inclusion into a nationally
funded programmes. Several of the most recently approved vaccines, including
Gardasil, have achieved a high price across markets. Despite this stakeholders are
still looking to drive down the cost of these programs through application of ten-
ders, wherever possible, with increasing scrutiny over high cost products. The
trend for more specialist vaccines hasmeant that the national agencies are unable
to approve use in a national program due to them not fulfilling market criteria.
Specialist vaccines are viewed as not relevant for the national vaccination pro-
grammes resulting in funding through more standard drug pathways and poten-
tially non reimbursement in markets where this is not possible. CONCLUSIONS: A
standard vaccine pricing strategy cannot be adopted for specialist vaccines as this
is not relevant in most cases and in some instances patient willingness to pay
needs to be considered.
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A REVIEW OF EPIDEMIOLOGICAL LITERATURE ON THE BASIC REPRODUCTION
NUMBER FOR THE 2009 NOVEL STRAIN OF H1N1
Walker A, Murphy J, Hettle R, Plested M
HERON Evidence Development Ltd, Luton, UK
OBJECTIVES: In 2009 a novel variant of influenza H1N1 (nH1N1) spread rapidly,
causing the first recognised worldwide influenza pandemic since 1968. In measur-
ing the spread of pandemic influenza, the basic reproduction number, R0, is a
measure of the number of secondary cases resulting from a single primary case in
a naïve population. The purpose of our study was to review published estimates of
R0 that relate to the 2009 pandemic providing insight into the relationship between
reported R0 estimates and different settings and estimationmethods.METHODS:A
structured search of published studies in EMBASE.com was undertaken. Studies
reporting R0 based on primary data were included. Of those included, we extracted
point estimates and measures of variability for R0, in addition to the country, set-
ting, duration and time period for data sources, and the method of R0 estimation.
Trends in estimated R0 values by study characteristic were investigated. RESULTS:
A total of 184 studies were identified, and 23 studies were included in the review.
The reported estimates for R0 ranged from 1.00 to 3.30, with 75% of studies report-
ing an R0 between 1.22 and 2.3. Studies which used data captured earlier in the
pandemic generally estimated higher values than studies which used data cap-
tured later in the pandemic. Estimates of R0 were lower in studies that utilised
longer term data sets compared to shorter data sets. Bayesian methods estimated
lower R0 values than estimations based upon intrinsic growth rates. There was no
significant trend in estimates of R0 by country.CONCLUSIONS: The basic reproduc-
tion number of nH1N1 may have been overestimated by studies based on shorter
duration data sets captured earlier in the pandemic. Awareness of data and meth-
odological restrictions and the effect of this on study results could be vital to accu-
rately predict the spread of future pandemics.
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CARE ORGANIZATION AND AMBULATORY CARE SENSITIVE
HOSPITALIZATIONS FOR BACTERIAL PNEUMONIA
Obi EN, Thomas J
Purdue University, West Lafayette, IN, USA
OBJECTIVES: Understanding associations between care organization and ambula-
tory care sensitive bacterial pneumonia hospitalizations (A-BPHs) is important for
outcomes management and has important policy implications. We determined
rates of A-BPH among Medicaid beneficiaries and assessed association between
care organization and A-BPH. METHODS: A retrospective cohort analysis of Med-
icaid claims, enrollment, and encounter data was conducted. Sample inclusion
criteria were  18 y/o, and continuous eligibility in 2008. Exclusion criteria were a
nursing home stay, no claims, or dying in 2008. A-BPHs were identified based on
AHRQ prevention quality indicator specifications for bacterial pneumonia. Each
individual was placed in one of four groups based on whether continuously en-
rolled in Fee for Service (FFS), Care Management (CM), or Managed care (MC) sub-
programs; or whether switches between subprograms occurred in 2008. Persons
enrolled in CM entered through disability determination, while other groups had
no known disability indication. Logistic regression assessed association between
care organization and A-BPH adjusting for age, gender, ethnicity, Charlson comor-
bidity, state Medicaid region, and history of coronary heart disease, cerebrovascu-
lar accident, congestive heart failure, claudication, chronic obstructive pulmonary
disease, or diabetes mellitus in the 12 months prior to the study period. RESULTS:
A sample of 197,964 persons, with a mean age of 43 years, 70% female, and 75%
white was identified. Overall, 1,726 A-BPHs occurred, a rate of 872 per 100,000
persons. Although no significant difference was seen between individuals in MC or
individuals who switched subprograms as compared to individuals in FFS, individ-
uals enrolled in CM were less likely to have A-BPHs as compared to those in FFS
(Odds ratio  0.38, 95% CI  0.29 – 0.50, P  0.0001) after adjusting for covariates.
CONCLUSIONS: Enrollment in Care Management was associated with lower like-
lihood of ambulatory care sensitive bacterial pneumonia hospitalization even after
adjusting for risk factors.
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IMPACT OF 2005 MEASLES OUTBREAK IN THE UNITED STATES ON
IMMUNIZATION RATE AGAINST MEASLES
Dwibedi N, Cortina J
University of Houston, Houston, TX, USA
OBJECTIVES:Although therewere several campaigns to eradicatemeasles fromUS
by immunization, the outbreak of measles in 2005 was one of the major indicators
of re-emergence of measles. What is the impact of 2005 measles outbreak on im-
munization rate (against measles) in the following year (2006)? METHODS: A ret-
rospective cohort study was conducted using National Immunization Survey (NIS)
2004 and NIS 2006 datasets. The outcome variable was up-to-date immunization
record against measles. The treatment variable was the outbreak of measles in
2005. Year 2004 was considered for pre-outbreak period and year 2006 was consid-
ered for post-outbreak period. Age, gender, race/ethnicity, Hispanic origin and first
born status of child; number of people in household; age, marital status and edu-
cation of mother were controlled to obtain unconfounded causal relation. There-
fore, assumption of ignorability was met for this study. The stable unit treatment
value assumptionwas alsomet because of the nature of the study. Propensity score
matching method was used to make two groups comparable. Confound adjusted
logistic regression (using weighted matched controls) was conducted to estimate
the change in measles immunization rate in 2006 from 2004. RESULTS: A total of
60,867 data was collected during 2004 and 2006 NIS. Weighted population totals
11,871,692 observations, representing an average of theUS population of 19-35month
old children over the survey years. Confounders have shown good percent reduction
in bias after propensity scorematching. Odds ratiowas less than 1 and also significant
(OR0.560, p0.048) only for the treatment variable. CONCLUSIONS: Immunization
rate against measles has been decreased after the largest measles outbreak, and
this is a concerned matter in the perspective of public health. Community based
and nation-wide intervention for immunization is still necessary.
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Hedden E1, Jessop A1, Field RI2
1University of the Sciences, Philadelphia, PA, USA, 2Drexel University, Philadelphia, PA, USA
OBJECTIVES: Immunization Information Systems (IIS) were developed to improve
quality and efficiencies in healthmanagement. Policies that govern IIS systems are
complex, and may interact with other immunization record policies. This study
updates and expands on a 9-year-old survey.METHODS: IIS relevant statutes and
regulations in 50 states, 5 cities and Washington D.C. (N56) were identified
through legal databases and reviewed for content. Coding categories were derived
considering previous studies, including IIS authorization, covered entities, privacy
and information sharing, reporting, enforcement and similar provisionswithin the
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Privacy Rule and Family Educational Rights and Privacy Act. The Delphi technique
was used to obtain expert input for the coding document. The 131 variable coding
instrument received 93.7% agreement and a K- of .791. RESULTS: Including all
subsections, 984 laws across localities relate to immunization records. Within and
across localities, laws were grouped into 13 topic headings, including health, edu-
cation, licensing, vital statistics, and insurance. Of 36 (64%) localities that have laws
addressing IIS creation, 42% authorize and 58% require development. Locality
adoption of these laws increased 50% since the previous study. While 24 (43%)
localities have specific IIS laws, 34 (61%) have IIS provisions within other laws.
Many others may not specify IIS, but do regulate collection, sharing and/or storage
of immunization data within education, department of health or other records.
Aggregate data for the localities is presented in tabular format and shaded maps.
CONCLUSIONS: Locality IIS policies have increased, HEDIS measures incorporate
childhood immunizations, and now Meaningful Use incentives include IIS partic-
ipation. Expanding adoption of policies encouraging participation may suggest a
diffusion of innovation, through both national and state channels. As entrepreneur
localities experiment to improve IIS utility and uniformity, it will be important to
consider how the current framework has influenced participation, and opportuni-
ties for future coordination through policy development.
Infection – Research on Methods
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COMPARISON OF EVIDENCE-BASED VARIATION AND CONSTANT PERCENTAGE
VARIATION FOR ONE-WAY SENSITIVITY ANALYSES
McQueen RB, Libby A, Campbell J
University of Colorado, Aurora, CO, USA
OBJECTIVES: A common approach to one-way sensitivity analysis is to vary inputs
by a constant percentage. An alternative is to derive ranges using evidence-based
probability distributions from published sources. Our objective was to compare
one-way sensitivity analysis results when using these two approaches in the same
decisionmodel.METHODS:We replicated a published HIV/AIDS cost-effectiveness
Markov model (zidovudine vs. zidovudine plus lamivudine in the UK) using Tree-
Age®. Health states included three HIV/AIDS states and death. We generated one-
way sensitivity analyses by varying inputs in twoways: 1) using15% for all inputs,
and 2) using the 2.5 and 97.5 percentile values of the evidence-based probability
distributions for all inputs.We compared the decisionuncertainty in the incremen-
tal cost-effectiveness ratios (ICERs) for each variation method as reflected by the
difference of the lower and upper range of ICERs for all inputs. Our outcome of
interestwas themeandifference in ICERuncertaintybetweeneachmethod for the ten
most influential inputs. Additionally, we assessed the number of inputs that would
have led to an inconclusive decision for eachmethodwherehighdecisionuncertainty
exists (e.g., in this example, a willingness-to-pay (WTP) of £10,000/QALY). RESULTS:
The deterministic ICER was £7,654/QALY for combination therapy vs. mono-
therapy. Themean difference in ICER uncertainty for the evidence-based vs.15%
variation method was £3,251/QALY (p0.0096). At a WTP of £10,000/QALY, four
inputs would have led to an inconclusive decision to adopt combination therapy
using the evidence-based variation method compared to no inputs using the con-
stant percentage variation method. CONCLUSIONS: In this case, the magnitude of
uncertainty in the outcome was larger for the evidence-based variation method
compared to the constant percentage variation method. Evidence-based uncer-
tainty in inputs should be used in all sensitivity analyses to reflect realistic uncer-
tainty in an outcome and aid decision-making about future research strategies.
Muscular-Skeletal Disorders – Clinical Outcomes Studies
PMS1
DO BISPHOSPHONATES CAUSE ATYPICAL FEMUR FRACTURES?
Mann J, Talbert J
University of Kentucky, Lexington, KY, USA
OBJECTIVES: Clinical case reports support the occurrence of atypical fractures
while Phase III trials for bisphosphonates have not shown this adverse effect. This
study determines whether or not atypical fractures of the subtrochanteric region
and diaphyseal femur are occurring in bisphosphonate users within the Kentucky
Medicaid population. The incidence of atypical femur fractures in bisphosphonate
users has been estimated at 30 per 100,000 person years.1 Bisphosphonates are
commonly prescribed for the prevention of osteoporosis-related fractures,2 but
there are concerns about this possible, but rare, adverse event related to the long-
term use of bisphosphonates.3,4 METHODS: The retrospective Kentucky Medicaid
claims based study assesses the risk of atypical fracture in bisphosphonate treated
patients versus non-bisphosphonate treated patients, who experienced a baseline
fracture. Of the 19,988 patients, aged 45-95, 2,440 of them used a bisphosphonate
for at least 180 days. RESULTS: There were 209 patients experiencing an atypical
fracture. Baseline fractures were grouped and those experiencing atypical frac-
tures versus those who didn’t are as follows: humerus (1.95% vs 0.97%), lower
extremity (3.04% vs 0.97%) and vertebral (1.58% vs 0.95%). Unadjusted analysis
indicated that bisphosphonate users are two times more likely to have atypical
fracture (OR: 2.2271 95% CI: 1.6123-3.0758). Adjusting for demographics, baseline
fracture, Charlson comorbidity index, and use of corticosteroids the patients who
used a bisphosphonate for at least 6 months were 1.92 times more likely to have
atypical fracture than non-users (95% CI: 1.365-2.688). Age was a significant predic-
tor in themultivariatemodel; bisphosphonate users, 65 and older,were three times
more likely to have an atypical fracture (OR: 3.187 p value0.001). CONCLUSIONS:
While a relationship between bisphosphonate use and atypical fractures is pres-
ent, the preventative function of other fractures dictates continued therapy. How-
ever, more research is needed to determine if a certain subtype of patients can be
identified to prevent future atypical fractures.
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ATRIAL FIBRILLATION IN OSTEOPOROTIC WOMEN TREATED WITH
ALENDRONATE
Chang LC1, Kao YH1, Hsiao FY2, Tsai YW1, Huang WF1
1Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan,
2National Taiwan University, Taipei, Taiwan
BACKGROUND: Bisphosphonates have been associated with an increased risk of
atrial fibrillation (AF) and may thus be associated with an increased risk of cardio-
vascular (CV) events. However, recent studies have so far not confirmed the poten-
tial risk of CV events associated with bisphosphonate use. In addition, whether the
CV risk associated with continuous bisphosphonate use remains an unanswered
clinical question. OBJECTIVES: The purpose of this study was to assess the CV risk
including AF, stroke, or acute myocardial infarction in osteoporotic women ex-
posed to oral bisphosphonates for at least three months.METHODS:We used the
2000-2008 Taiwan’s National Health Insurance Program to conduct a popula-
tion-based, cross-over study of 10,572 newly diagnosed osteoporotic women.
Eligible patients were those who had taken alendronate, 10 mg or 70 mg, for at
least three months. Study subjects were further categorized into continuous
and discontinued users. Cox proportional models were used to compare the
1-year risk of CV events between continuous and discontinued users. RESULTS:
Among the 10,572 osteoporotic women, 8,852 received a weekly regimen of
alendronate 70 mg while 1720 received a daily regimen of alendronate 10mg.
More than 80% of alendronate users continued their therapy after the first three
months. The cumulative exposure of alendronate were 285 and 104 days (alen-
dronate 70mg) and 251 and 96 days (alendronate 10mg) in continuous and dis-
continued users, respectively. Compared to discontinued user, continuous
use of alendronate was not associated with a higher risk of CV events.
These findings were consistent among the users of alendronate 70mg
(HR1.06, 95%CI0.80-1.39) and alendronate 10mg (HR0.67, 95%CI0.42-1.06).
CONCLUSIONS: Continuous alendronate use was not significantly associated with
an increased CV risk in osteoporotic women.
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RISK FACTORS FOR NON-INITIATION OF DISEASE MODIFYING
ANTI-RHEUMATIC DRUGS (DMARD) BY PATIENTS WITH NEWLY
DIAGNOSED RHEUMATOID ARTHRITIS (RA)
Bonafede M1, Johnson BH2, Fox KM3, Watson C4, Gandra SR5
1Thomson Reuters, Andover, MA, USA, 2Thomson Reuters, Washington, DC, USA, 3Strategic
Healthcare Solutions, LLC, Monkton, MD, USA, 4Amgen, Inc., Newbury Park, CA, USA, 5Amgen,
Inc., Thousand Oaks, CA, USA
OBJECTIVES: To evaluate adoption of treatment guidelines recommending the ini-
tiation of a DMARD within 12 months of new RA diagnosis and to identify risk
factors for non-initiation. METHODS: Newly diagnosed adult RA patients from
2003-2009 with 12 months of continuous enrollment before and after their first RA
diagnosis were identified in the MarketScan Research Databases®. Patients were
excluded if they used a biologic or conventional DMARD prior to their first diagno-
sis. Patients were categorized as DMARD initiators or non-initiators in the 12
months following diagnosis (follow-up period). We compared demographic and
clinical characteristics of initiators versus non-initiators using Cox-proportional
hazard models. RESULTS: A total of 26,911 patients met the study criteria; 17,014
patients (63%) initiated a DMARD therapy in the follow-up period. At baseline, com-
pared to initiators, non-initiators were older [mean age 62.6 (SD14.9) versus 58.1
(SD13.3), p0.001], had a higher Deyo-Charlson Comorbidity Index Score (CCI) [0.76
(SD1.3) versus 0.58 (SD1.1), p0.001],weremore likely tohavehadan inpatient stay
in the pre-index period (19% versus 13%, p0.001), had higher pre-index total costs
[$12,725 (SD$24,500) versus $10,534 (SD$20,259), p0.001] and had similar out-of-
pocket total costs [$1,224 (SD$1,370) versus $1,230 (SD$1,519), p0.738)] and out-
of-pocket outpatient pharmacy costs [$492 (SD$611) versus $478 (SD$553),
p0.052]. Multivariate-adjusted risk factors for DMARD non-initiation included older
age (85), high CCI (3), and the presence of GI disorders, cardiac conditions, hyper-
tension, osteoarthritis, or respiratory infections in the pre-index period. Patients who
used an NSAID or corticosteroid, were diabetic, saw a rheumatologist, or had a rheu-
matoid factor test in the pre-index period were all more likely to initiate a DMARD in
the follow-up period. CONCLUSIONS: The majority of new RA patients followed
treatment guidelines and initiated a DMARD therapy; nevertheless, over one-third
of the patients did not initiate DMARD therapy within a year after diagnosis.
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THE ASSOCIATION BETWEEN TERIPARATIDE PERSISTENCE AND FRACTURE
OUTCOMES IN A US CLAIMS DATABASE
Yu S1, Foster S2, Burge R2, Anderson J2, Gelwicks S2, Meadows E2
1University of Illinois at Chicago, Chicago, IL, USA, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To evaluate the association between persistence on teriparatide
(TPTD) treatment and fracture incidence rate and fracture risk among US patients.
METHODS: We used the Thomson Reuters MarketScan® Research Databases,
2004-2008, to identify new TPTD users 18 years with continuous medical and
pharmacy coverage over 12-months pre-index and 24-months post-index date (in-
dex datefirst TPTD prescription). Pathologic fractures, traumatic or clustered
fracture events (3) occurring within 7 days, fractures within 90 days of index date
or at the same site, and any hip fractures after 2nd occurrence were excluded from
the post-index osteoporotic fracture definition. Persistence was measured as total
days on TPTD until first 45-day gap. Logistic regressions were performed to model
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